BACKGROUND: In vitro studies suggest basal breast cancers are more sensitive to gemcitabine relative to other intrinsic subtypes. The main objective of this study was to use specimens from a randomized clinical trial to evaluate whether the basal-like subtype identifies patients with advanced breast cancer who benefit fromgemcitabine plus docetaxel (GD) compared to single agent docetaxel (D). MATERIAL AND METHODS: From patients randomly assigned to GD or D, RNA was isolated from archival formalin-fixed, paraffin-embedded primary breast tumor tissue and used for PAM50 intrinsic subtyping by NanoString nCounter. Statistical analyses were prespecified as a formal prospective-retrospective clinical trial correlative study. Using time to progression (TTP) as primary endpoint, overall survival (OS) and response rate as secondary endpoints, relationships between subtypes and outcome after chemotherapy were analyzed by the Kaplan-Meier method, and Cox proportional hazards regression models. Data analysis was performed independently by the Danish Breast Cancer Cooperative Group (DBCG) statistical core and all statistical tests were two-sided. RESULTS: RNA from 270 patients was evaluable; 84 patients (31%) were classified as luminal A, 97 (36%) luminal B, 43 (16%) basal-like, and 46 (17%) as HER2-enriched. PAM50 intrinsic subtype was a significant independent prognostic factor for both TTP (p=0.014) and OS (p=0.0003). Response rate was not different by subtype, and PAM50 was not a predictor of TTP by treatment arm. PAM50 was however a highly significant predictor of OS following GD compared to D (pinteraction=0.0016). Patients with a basal-like subtype had a significant reduction in OS events [hazard ratio (HR)=0.29, 95% confidence interval (CI)=0.15-0.57; pinteraction=0.0006]. CONCLUSION: A significantly improved and clinically important prolongation of survival was seen from the addition of gemcitabine to docetaxel in advanced basal-like breast cancer patients.
RCT Entities:
BACKGROUND: In vitro studies suggest basal breast cancers are more sensitive to gemcitabine relative to other intrinsic subtypes. The main objective of this study was to use specimens from a randomized clinical trial to evaluate whether the basal-like subtype identifies patients with advanced breast cancer who benefit from gemcitabine plus docetaxel (GD) compared to single agent docetaxel (D). MATERIAL AND METHODS: From patients randomly assigned to GD or D, RNA was isolated from archival formalin-fixed, paraffin-embedded primary breast tumor tissue and used for PAM50 intrinsic subtyping by NanoString nCounter. Statistical analyses were prespecified as a formal prospective-retrospective clinical trial correlative study. Using time to progression (TTP) as primary endpoint, overall survival (OS) and response rate as secondary endpoints, relationships between subtypes and outcome after chemotherapy were analyzed by the Kaplan-Meier method, and Cox proportional hazards regression models. Data analysis was performed independently by the Danish Breast Cancer Cooperative Group (DBCG) statistical core and all statistical tests were two-sided. RESULTS: RNA from 270 patients was evaluable; 84 patients (31%) were classified as luminal A, 97 (36%) luminal B, 43 (16%) basal-like, and 46 (17%) as HER2-enriched. PAM50 intrinsic subtype was a significant independent prognostic factor for both TTP (p=0.014) and OS (p=0.0003). Response rate was not different by subtype, and PAM50 was not a predictor of TTP by treatment arm. PAM50 was however a highly significant predictor of OS following GD compared to D (pinteraction=0.0016). Patients with a basal-like subtype had a significant reduction in OS events [hazard ratio (HR)=0.29, 95% confidence interval (CI)=0.15-0.57; pinteraction=0.0006]. CONCLUSION: A significantly improved and clinically important prolongation of survival was seen from the addition of gemcitabine to docetaxel in advanced basal-like breast cancerpatients.
Authors: Susanne R Youngren-Ortiz; David B Hill; Peter R Hoffmann; Kenneth R Morris; Edward G Barrett; M Gregory Forest; Mahavir B Chougule Journal: J Aerosol Med Pulm Drug Deliv Date: 2017-03-09 Impact factor: 2.849
Authors: Elisabeth S Stovgaard; Karama Asleh; Nazia Riaz; Samuel Leung; Dongxia Gao; Lise B Nielsen; Anne-Vibeke Lænkholm; Eva Balslev; Maj-Britt Jensen; Dorte Nielsen; T O Nielsen Journal: Oncoimmunology Date: 2021-05-11 Impact factor: 8.110
Authors: Brett Wallden; James Storhoff; Torsten Nielsen; Naeem Dowidar; Carl Schaper; Sean Ferree; Shuzhen Liu; Samuel Leung; Gary Geiss; Jacqueline Snider; Tammi Vickery; Sherri R Davies; Elaine R Mardis; Michael Gnant; Ivana Sestak; Matthew J Ellis; Charles M Perou; Philip S Bernard; Joel S Parker Journal: BMC Med Genomics Date: 2015-08-22 Impact factor: 3.063
Authors: Charlotte Levin Tykjær Jørgensen; Christina Bjerre; Bent Ejlertsen; Karsten D Bjerre; Eva Balslev; Annette Bartels; Nils Brünner; Dorte L Nielsen Journal: BMC Cancer Date: 2014-05-22 Impact factor: 4.430
Authors: Govind Babu; A Goel; S Agarwal; S Gupta; P Kumar; B K Smruti; V Goel; R Sarangi; M Gairola; S Aggarwal; Purvish M Parikh Journal: South Asian J Cancer Date: 2018 Apr-Jun